Health and Healthcare

Pfizer : PFE

All Pfizer Articles

1490 Articles

Chris Lange | Oct 12, 2015 at 9:25 AM EDT

Short Sellers Become More Selective on Major Pharma

The September 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical…

Paul Ausick | Sep 28, 2015 at 4:01 PM EDT

The 4 Stocks That Sank the DJIA on Monday

thinkstockSeptember 28, 2015: Markets opened lower on Monday following a report that personal income rose just 0.3% in August, short of…

Chris Lange | Sep 25, 2015 at 8:40 AM EDT

Short Sellers Boost Positions in Major Pharma

The September 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical…

Lee Jackson | Sep 24, 2015 at 9:45 AM EDT

Merrill Lynch Has 4 Pharma Stocks to Buy Against Political Chatter

One positive from the hammering the pharmaceutical stocks have taken is the Merrill Lynch analysts say investors have been given…

Chris Lange | Sep 11, 2015 at 8:25 AM EDT

Short Sellers Become More Selective in Major Pharma

The short interest data have been released for the August 31 settlement date, and for the selected pharmaceutical stocks, short…

Paul Ausick | Sep 10, 2015 at 4:01 PM EDT

The 4 Stocks That Lifted the Dow on Thursday

thinkstockSeptember 10, 2015: Markets opened lower on Thursday after a rather lackluster performance in Asia’s equity markets and more of…

Paul Ausick | Sep 8, 2015 at 4:01 PM EDT

The 4 Stocks That Lifted the DJIA Higher Tuesday

thinkstockSeptember 8, 2015: Markets opened higher on Tuesday following reports that the Chinese government would pump more liquidity into the…

Trey Thoelcke | Sep 2, 2015 at 10:05 AM EDT

The Best and Worst Dow Performers During the Recent Collapse

As in all outbreaks of volatility, there are islands of relative stability drowned out by the companies causing the loudest…

Paul Ausick | Aug 31, 2015 at 4:01 PM EDT

The 4 Stocks That Hobbled the Dow on Monday

thinkstockAugust 31 2015: Markets opened lower on Monday, but even a massive rally in crude oil couldn’t keep the bears…

Paul Ausick | Aug 28, 2015 at 4:01 PM EDT

The 4 Stocks That Held Down the DJIA on Friday

thinkstockAugust 28, 2015: Markets opened lower on Friday, and except for a brief visit above the break-even line, the blue…

Chris Lange | Aug 28, 2015 at 9:35 AM EDT

Meet the Newest Additions to the S&P 500

The S&P 500 is adding two new components: Activision Blizzard and United Continental.

Lee Jackson | Aug 27, 2015 at 9:15 AM EDT

Deutsche Bank Says Stick With Top Stocks Growing Dividends

If investors have dry powder or have raised cash by selling higher beta momentum stocks, these stocks may make good…

Chris Lange | Aug 26, 2015 at 8:05 AM EDT

Short Sellers Have Mixed Feelings on Major Pharma

The August 14 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short…

Jon C. Ogg | Aug 24, 2015 at 2:09 PM EDT

Pfizer Gets Approval For Hospira Acquisition

ThinkstockAt a time when there is pressure on how large US companies are making domestic or overseas acquisitions are coming…

Lee Jackson | Aug 24, 2015 at 10:50 AM EDT

4 Event-Driven Stocks to Buy for the Rest of 2015

A new research note from Jefferies lists stocks that could have meaningful events soon. The stocks in some cases have…

1 … 57 58 59 60 61 … 100

Pfizer : PFE

All Pfizer Articles

Short Sellers Become More Selective on Major Pharma

The 4 Stocks That Sank the DJIA on Monday

Short Sellers Boost Positions in Major Pharma

Merrill Lynch Has 4 Pharma Stocks to Buy Against Political Chatter

Short Sellers Become More Selective in Major Pharma

The 4 Stocks That Lifted the Dow on Thursday

The 4 Stocks That Lifted the DJIA Higher Tuesday

The Best and Worst Dow Performers During the Recent Collapse

The 4 Stocks That Hobbled the Dow on Monday

The 4 Stocks That Held Down the DJIA on Friday

Meet the Newest Additions to the S&P 500

Deutsche Bank Says Stick With Top Stocks Growing Dividends

Short Sellers Have Mixed Feelings on Major Pharma

Pfizer Gets Approval For Hospira Acquisition

4 Event-Driven Stocks to Buy for the Rest of 2015

SETM Is Up 27% YTD and 150% Over a Year. The S&P 500? Not Even Close.

A 61-Year-Old Widow Claimed Survivor Benefits While Still Working, Then the Earnings Test Triggered a $1-for-$2 Clawback

A Covered Call ETF That Pays 6% Is Beating Vanguard’s Biggest International ETF Right Now

A 61-Year-Old Widow Claimed Survivor Benefits While Still Working, Then the Earnings Test Triggered a $1-for-$2 Clawback

Suze Orman to 54-Year-Old With $600,000: Skip the 1.5% Fee and Manage It Yourself

SETM Is Up 27% YTD and 150% Over a Year. The S&P 500? Not Even Close.

A 61-Year-Old Widow Claimed Survivor Benefits While Still Working, Then the Earnings Test Triggered a $1-for-$2 Clawback

Pfizer : PFE

All Pfizer Articles

Short Sellers Become More Selective on Major Pharma

The 4 Stocks That Sank the DJIA on Monday

Short Sellers Boost Positions in Major Pharma

Merrill Lynch Has 4 Pharma Stocks to Buy Against Political Chatter

Short Sellers Become More Selective in Major Pharma

The 4 Stocks That Lifted the Dow on Thursday

The 4 Stocks That Lifted the DJIA Higher Tuesday

The Best and Worst Dow Performers During the Recent Collapse

The 4 Stocks That Hobbled the Dow on Monday

The 4 Stocks That Held Down the DJIA on Friday

Meet the Newest Additions to the S&P 500

Deutsche Bank Says Stick With Top Stocks Growing Dividends

Short Sellers Have Mixed Feelings on Major Pharma

Pfizer Gets Approval For Hospira Acquisition

4 Event-Driven Stocks to Buy for the Rest of 2015

SETM Is Up 27% YTD and 150% Over a Year. The S&P 500? Not Even Close.

A 61-Year-Old Widow Claimed Survivor Benefits While Still Working, Then the Earnings Test Triggered a $1-for-$2 Clawback

A Covered Call ETF That Pays 6% Is Beating Vanguard’s Biggest International ETF Right Now

Featured Reads

A 61-Year-Old Widow Claimed Survivor Benefits While Still Working, Then the Earnings Test Triggered a $1-for-$2 Clawback

Suze Orman to 54-Year-Old With $600,000: Skip the 1.5% Fee and Manage It Yourself